-
LIVERMULTISCAN AS A NON-INVASIVE ALTERNATIVE TO LIVER BIOPSY FOR MONITORING PAEDIATRIC AUTOIMMUNE HEPATITIS: A MULTI-REGION ECONOMIC EVALUATION
Feb 25, 2026, 14:40 PM -
POINT-OF-CARE TESTS FOR PEDIATRIC URINARY TRACT INFECTIONS: SYSTEMATIC REVIEW AND META-ANALYSIS
Feb 25, 2026, 14:40 PM -
TRENDS IN ATOPIC DERMATITIS MEDICATION UTILIZATION AND PHARMACY COSTS IN PEDIATRIC COMMERCIAL AND MEDICAID POPULATIONS
Feb 25, 2026, 14:40 PM -
COMPARISON OF HEALTHCARE COSTS BETWEEN RECONSTRUCTION PROCEDURE AND DIRECT AMPUTATION OF LOWER EXTREMITIES AMONG PATIENTS WITH DIABETIC NEUROPATHIC ARTHROPATHY
Feb 25, 2026, 14:40 PM -
TREATMENT PATTERNS AND HEALTH-RELATED QUALITY OF LIFE ACROSS DISEASE STAGES AMONG A REAL-WORLD SAMPLE OF PATIENTS WITH MIXED PHENOTYPE TRANSTHYRETIN AMYLOIDOSIS
Feb 25, 2026, 14:40 PM -
COST-EFFECTIVENESS AS THE NEXT POLICY LEVER IN THE UNITED STATES? IMPLICATIONS FOR PHARMACEUTICAL PRICING IN A POST-MFN LANDSCAPE
Feb 25, 2026, 14:40 PM -
?ECONOMIC IMPACT OF PET-18FLUTEMETAMOL GUIDED TREATMENT ALLOCATION IN THE DIAGNOSIS AND MANAGEMENT OF ALZHEIMER DISEASE. A BUDGET IMPACT MODEL FOR EUROPEAN PAYERS...
Feb 25, 2026, 14:40 PM -
DIRECT MEDICAL COSTS SAVED BY EARLY PAH DETECTION USING A MACHINE LEARNING ALGORITHM
Feb 25, 2026, 14:40 PM -
TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTR-CM) TREATMENT PREFERENCES AMONG PATIENTS AND CARDIOLOGISTS: FINDINGS FROM TWO ADVISORY BOARDS IN THE UNITED STATES
Feb 25, 2026, 14:40 PM -
EVALUATING THE IMPACT OF MONETARY INCENTIVES ON HEALTH EQUITY : A DISTRIBUTIONAL COST-EFFECTIVENESS ANALYSIS OF COVID-19 VACCINATION STRATEGIES
Feb 25, 2026, 14:40 PM -
VALIDATION OF DIAGNOSES CODES FOR IDENTIFYING PATIENTS WITH HEPATITIS C VIRUS IN EHR IN A US, REAL-WORLD POPULATION
Feb 25, 2026, 14:40 PM -
QUANTIFYING THE LIFETIME HEALTH AND SOCIETAL BENEFITS OF TIMELY DIAGNOSIS AND ACCESS TO APPROVED TREATMENTS IN ANTI-ACETYLCHOLINE RECEPTOR ANTIBODY-POSITIVE (ACHR-AB+) GENERALIZED MYASTHENIA GRAVIS (GMG) IN THE UNITED STATES
Feb 25, 2026, 14:40 PM -
EARLY IDENTIFICATION OF POSTPARTUM DEPRESSION RISK USING ARTIFICIAL INTELLIGENCE
Feb 25, 2026, 14:40 PM -
UTILIZATION OF TARLATAMAB AND ASSOCIATED HEALTHCARE RESOURCE USE, COSTS, AND ADVERSE EVENTS: A RETROSPECTIVE COHORT STUDY USING A LARGE U.S. HOSPITAL DATABASE
Feb 25, 2026, 14:40 PM -
BEYOND THE SINGLE QALY: CHALLENGES IN APPLYING NON-HALY OUTCOMES IN ECONOMIC EVALUATIONS
Feb 25, 2026, 14:40 PM -
COMPARATIVE EFFECTIVENESS ANALYSIS OF FOLFIRINOX AND GEMCITABINE PLUS NAB-PACLITAXEL IN METASTATIC PANCREATIC ADRENOCARCINOMA; USING MARGINAL STRUCTURAL MODEL
Feb 25, 2026, 14:40 PM -
DOES SUBSTANDARD CANCER CARE ADVERSELY IMPACT PATIENT FINANCIAL WELL BEING? AN ANALYSIS OF CANCER REGISTRY, CLAIMS, AND CREDIT REPORT SCORES
Feb 25, 2026, 14:40 PM -
CHARACTERIZING THE USE OF DIGITAL HEALTH TECHNOLOGY-DERIVED ENDPOINTS TO CAPTURE PATIENT EXPERIENCE DATA IN CLINICAL TRIALS
Feb 25, 2026, 14:40 PM -
REAL WORLD HEALTHCARE RESOURCE UTILIZATION AND COSTS IN METASTATIC COLORECTAL CANCER (MCRC) PATIENTS BY LINE OF THERAPY IN THE UNITED STATES
Feb 25, 2026, 14:40 PM -
THE ROLE OF SAFETY AND TOLERABILITY IN HTA VALUE ASSESSMENT: EVIDENCE REQUIREMENTS AND IMPACT ACROSS KEY EUROPEAN MARKETS
Feb 25, 2026, 14:40 PM
